The Point of Health

POINT Biopharma is a clinical-stage pharmaceutical company focused on the development and commercialization of precision radioligand therapies for the treatment of cancer. The company's lead programs target well-validated cancer markers such as PSMA and SSTR, utilizing proprietary ligands and radioisotopes like Lutetium-177 to deliver targeted radiation directly to tumor cells. POINT Biopharma operates a large-scale, state-of-the-art radiopharmaceutical manufacturing facility in Indianapolis, ensuring a reliable supply chain for its clinical and future commercial products. In late 2023, the company was acquired by Eli Lilly, significantly expanding Lilly's oncology portfolio into the rapidly growing radiopharmaceutical space.